Clinical trial reportJournal of clinical oncology : official journal of the American Society of Clinical OncologyPublished
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study
Regional connection
Verified An author affiliation on the Europe PMC record names Fox Chase Cancer Center, with Temple Health linked by the institution reference. Affiliation source
- Institutions
- Fox Chase Cancer Center, Temple Health
- County
- Philadelphia County
Publication record
- Type
- Clinical trial report
- Venue
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Published
- Topic
- Clinical care
- Subject terms
- T-Lymphocytes; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Antineoplastic Agents; Antibodies, Bispecific; Ligands; Small Cell Lung Carcinoma
- PubMed ID
- 36689692
- PubMed Central ID
- PMC10414718
- Open access
- Yes, open
- Added to directory
- Source checked